| Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results) (NCT05496530) | Benha University | 2022-07-10 |
| Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion (NCT05532475) | Kasr El Aini Hospital | 2022-03-12 |
| Anti-VEGF in Real-world (NCT05222633) | Wenbin Wei | 2022-01-01 |
| High Resolution Optical Coherence Tomography (NCT05130385) | Insel Gruppe AG, University Hospital Bern | 2021-11-30 |
| Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection (NCT05003258) | Assiut University | 2021-10-07 |
| NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients (NCT05133791) | University Medical Center Groningen | 2021-09-23 |
| Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study (NCT04011358) | Centre Hospitalier Régional d'Orléans | 2021-09-01 |
| Efficacy of Formulated Posterior Sub Tenon Triamcinolone in Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusions (NCT05345808) | Al-Azhar University | 2021-03-01 |
| Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema (NCT04847869) | University of Sydney | 2021-01-01 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients (NCT04635800) | Novartis Pharmaceuticals | 2020-12-10 |
| Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections (NCT04563299) | Retina Vitreous Associates of Florida | 2020-12-09 |
| A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (NCT04592419) | Kodiak Sciences Inc | 2020-09-25 |
| Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents (NCT04395859) | Fondation Ophtalmologique Adolphe de Rothschild | 2020-05-27 |
| Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections (NCT04142164) | Prim. Prof. Dr. Oliver Findl, MBA | 2019-10-24 |
| Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion (NCT04062370) | Sun Yat-sen University | 2019-10-01 |
| Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease (NCT04505618) | Johns Hopkins University | 2019-10-01 |
| Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion (NCT04075695) | Renmin Hospital of Wuhan University | 2019-09-18 |
| The Use of Suprachoroidal Triamcinolone Acetonide to Treat Macular Edema in Retinal Vein Occlusion (NCT05038072) | Damascus University | 2019-07-25 |
| Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (NCT03908307) | Allergan | 2019-07-25 |
| Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO (NCT03790852) | Kodiak Sciences Inc | 2018-12-26 |
| Post Intravitreal Injection Topical NSAID vs. Patching (NCT03918590) | The New York Eye & Ear Infirmary | 2018-12-03 |
| Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies (NCT03680794) | CHU de Reims | 2018-06-27 |
| Correlation Between the Visual Acuity & the OCT Pattern of Macular Edema Secondary to RVO (NCT03489915) | Assiut University | 2018-05-01 |
| Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO (NCT03203447) | Clearside Biomedical, Inc. | 2018-03-05 |
| Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion (NCT06757595) | Zhongnan Hospital | 2018-01-01 |
| TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) (NCT03093701) | Taiwan Liposome Company | 2017-04-01 |
| Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept (NCT03056079) | Unity Health Toronto | 2017-02-28 |
| Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab (NCT03056092) | Unity Health Toronto | 2017-02-28 |
| Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO (NCT02980874) | Clearside Biomedical, Inc. | 2017-01-31 |
| 30g vs 33g Needle for Intravitreal Injections (NCT03038048) | Wills Eye | 2017-01-27 |
| Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept (NCT02880644) | Centre Hospitalier Intercommunal Creteil | 2017-01-26 |
| Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (NCT06416241) | University of Athens | 2017-01-01 |
| Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201 (NCT02956330) | Clearside Biomedical, Inc. | 2016-11-01 |
| Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning (NCT02898480) | University of Aarhus | 2016-09-01 |
| Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion (NCT02645747) | Bayer | 2016-01-21 |
| Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) (NCT03525132) | University Hospital, Grenoble | 2015-09-18 |
| Retinal Thrombosis and Atherosclerosis (NCT02257333) | University of Roma La Sapienza | 2015-09-01 |
| Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO (NCT02503540) | Justis Ehlers | 2015-08-18 |
| SD-OCT Angiography (NCT02510885) | Duke University | 2015-07-01 |
| Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. (NCT02140411) | Novartis Pharmaceuticals | 2015-04-25 |
| Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection (NCT02486484) | Rafic Hariri University Hospital | 2015-03-01 |
| Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME. (NCT02571972) | Wills Eye | 2015-02-01 |
| Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO (NCT02303184) | Clearside Biomedical, Inc. | 2015-01-01 |
| Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO (NCT02387788) | Aerpio Therapeutics | 2015-01-01 |
| Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (NCT02245516) | Kala Pharmaceuticals, Inc. | 2014-07-01 |
| Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX® (NCT02181530) | Allergan | 2014-07-01 |
| Resistance to Antibiotics in Patients Receiving Eye Injections (NCT02126423) | Prism Vision Group | 2014-05-01 |
| A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema (NCT01918371) | Allergan | 2013-08-02 |
| Ocular Manifestations in Rheumatic Diseases (NCT03753893) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2013-05-01 |
| Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion (NCT02614937) | Ohr Pharmaceutical Inc. | 2013-04-01 |
| Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging (NCT01717937) | University of California, San Francisco | 2013-02-01 |
| Ozurdex for Retinal Vein Occlusion Study (ORVO Study) (NCT01790685) | Johns Hopkins University | 2013-02-01 |
| Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE) (NCT01875770) | Johns Hopkins University | 2013-01-01 |
| Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO (NCT01692938) | Optos, PLC | 2012-10-01 |
| National Eye Institute Biorepository for Retinal Diseases (NCT01496625) | National Eye Institute (NEI) | 2012-06-18 |
| Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO (NCT01580020) | Novartis Pharmaceuticals | 2012-05-01 |
| Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion (NCT01809236) | Chengdu Kanghong Biotech Co., Ltd. | 2012-05-01 |
| A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO) (NCT01571557) | Allergan | 2012-04-30 |
| Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion (NCT01566526) | Allergan | 2012-03-01 |
| A Long-Term Safety Study of OZURDEX® in Clinical Practice (NCT01539577) | Allergan | 2012-03-01 |
| Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF (NCT02118831) | California Retina Consultants | 2012-03-01 |
| Minocycline to Treat Central Retinal Vein Occlusion (NCT01468844) | National Eye Institute (NEI) | 2011-12-21 |
| Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion (NCT01618266) | Allergan | 2011-11-01 |
| Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion (NCT01427751) | Allergan | 2011-10-11 |
| Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. (NCT01449682) | Retina Macula Institute | 2011-10-01 |
| Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion (NCT01428388) | Barnes Retina Institute | 2011-09-01 |
| Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion (NCT01581151) | Brian Burke, MPH | 2011-09-01 |
| DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO) (NCT01662518) | Centro de Pesquisa Rubens Siqueira | 2011-07-01 |
| Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO) (NCT01411696) | Allergan | 2011-07-01 |
| Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion (NCT01377597) | Novartis Pharmaceuticals | 2011-06-01 |
| Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea (NCT01976650) | Allergan | 2011-03-01 |
| Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (NCT01318941) | Novartis Pharmaceuticals | 2011-03-01 |
| Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) (NCT01225146) | David M. Brown, M.D. | 2010-10-01 |
| Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion (NCT01198327) | Peter A Campochiaro, MD | 2010-08-01 |
| Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina (NCT02088151) | Insel Gruppe AG, University Hospital Bern | 2010-06-01 |
| Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium (NCT01573572) | Bausch & Lomb Incorporated | 2010-04-22 |
| Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO) (NCT01027650) | Allergan | 2010-03-01 |
| Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions (NCT01003106) | Peter A Campochiaro, MD | 2009-11-01 |
| Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion (NCT01011374) | Retina Associates of Cleveland, Inc | 2009-11-01 |
| Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) (NCT01012973) | Bayer | 2009-10-01 |
| Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion (NCT00970957) | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | 2009-09-01 |
| Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations (NCT00831350) | Barnes Retina Institute | 2009-04-01 |
| Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO) (NCT00942864) | Novartis Korea Ltd. | 2008-12-01 |
| An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2) (NCT01442064) | Genentech, Inc. | 2008-07-01 |
| Transcorneal Electrical Stimulation Therapy for Retinal Disease (NCT00804102) | Okuvision GmbH | 2008-01-01 |
| Ranibizumab in Patients With Branch Retinal Vein Occlusion (NCT01027481) | Medical University of Vienna | 2007-12-01 |
| Atorvastatin for the Treatment of Retinal Vein Occlusion (NCT00517257) | University of Toronto | 2007-08-01 |
| A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) (NCT00485836) | Genentech, Inc. | 2007-07-01 |
| A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO) (NCT00486018) | Genentech, Inc. | 2007-07-01 |
| Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema (NCT00403039) | Vitreous -Retina- Macula Consultants of New York | 2006-11-01 |
| To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions (NCT00493064) | Palo Alto Medical Foundation | 2006-10-01 |
| Radial Optic Neurotomy in Central Retinal Vein Occlusion : a Randomized Trial (NCT00379223) | University Hospital, Bordeaux | 2006-10-01 |
| Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions (NCT00407355) | Peter A Campochiaro, MD | 2006-01-01 |
| Combined Triple Procedure in Retinal Vein Occlusion (RVO) (NCT00805064) | Johann Wolfgang Goethe University Hospital | 2006-01-01 |
| Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage (NCT00106132) | National Eye Institute (NEI) | 2005-03-01 |
| A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion (NCT00168298) | Allergan | 2004-11-01 |
| A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion (NCT00168324) | Allergan | 2004-10-01 |
| The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study (NCT00105027) | The Emmes Company, LLC | 2004-10-01 |
| Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) (NCT00088283) | Eyetech Pharmaceuticals | 2004-05-01 |
| Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders (NCT00071227) | National Eye Institute (NEI) | 2003-10-15 |